Clinical Trial Update: A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM) [Phase 2]

View source ↗

Summary

Amgen completed a Phase 2 proof-of-concept trial evaluating the efficacy and safety of Daxdilimab in Dermatomyositis and anti-synthetase inflammatory myositis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-synthetase Syndrome
• Dermatomyositis
• Idiopathic Inflammatory Myopathy

Drugs mentioned

• DAXDILIMAB (daxdilimab)

Snippet

Sponsor: Amgen | Conditions: Idiopathic Inflammatory Myositis | Phase 2 | Status: COMPLETED